-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-6301 in Chordoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-6301 in Chordoma Drug Details: GI-6301 is under development for the treatment of chordoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Allergic Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Allergic Asthma Drug Details: GI-301 is under development for chronic idiopathic urticarial (CIU),...
-
Company Insights
New![]()
Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of General Interface Solution (GIS) Holding Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Chronic Urticaria Or Hives
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Chronic Urticaria Or Hives Drug Details: GI-301 is under development for chronic idiopathic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-301 in Atopic Dermatitis (Atopic Eczema) Drug Details: GI-301 is under development for chronic idiopathic...
-
Product Insights
New![]()
Net Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-XBI-302 in Graft Versus Host Disease (GVHD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-XBI-302 in Graft Versus Host Disease (GVHD) Drug Details: GI-XBI-302 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus InfectionsDrug Details:The vaccine candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-1200 in Gastrointestinal Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-1200 in Gastrointestinal Tumor Drug Details: MK-1200 is under development for the treatment of gastrointestinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLM1RA in Cardiovascular Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLM1RA in Cardiovascular Disease Drug Details: GLM1RA is under development for the treatment of gastrointestinal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.